The University of Birmingham has committed to create world-leading bioinformatics capacity and expertise with the creation of three prestigious bioinformatics chair-level positions.
The Bioinformatics Chairs are supported by a dedicated and creative team of bioinformatics research fellows, IT and administrative support staff. The CCB team works closely, drawing from their individual strengths and areas of interest to create a well-rounded knowledge base. The CCB team collaborates with University and external researchers, supporting them in their work. The CCB team has built strong links with bioinformaticians and related academics across the University, forming a network of working relationships, and building the CCB Community.
Roles we are recruiting for will be published on this page and the University's HR pages.
Develop and deliver postgraduate programmes in Bioinformatics including programmes based at the University of Birmingham Edgbaston and Dubai campuses and Distance Learning formats.
Contribute to undergraduate and postgraduate programmes in the School of Biosciences and to contribute to the management, leadership and enterprise activities of the School of Biosciences and the Centre for Computational Biology.
Closing Date: 12 April 2021
Play a pivotal role in enabling research to “Improve outcome for patients with Poor Risk Acute Myeloid Leukaemia” under the supervision of Professor Jean-Baptiste Cazier at the Centre for Computational Biology (CCB). Select and implement optimal integrative mathematical framework, tools, and approaches for the project, and take responsibility for the analysis and integration of Acute Myeloid Leukaemia (AML) data generated by the CRUK programme led by Professor Jude Fitzgibbon, Queen Mary University of London, in collaboration with numerous prestigious institutions.
This work will provide new insight into the biology of poor risk disease, will inform our existing translational studies that include ‘targeting the phospho proteome’ and ‘reawakening normal stem cell function’, and will fuel new and innovative research projects based on our data integration. The programme will lead to new clinical trial activity in the area of poor risk disease and the capability to align patients to treatments based on their underlying biochemical profiles.
Closing date 22 April 2021